Leaflet EPOPROSTENOL 0.5mg powder and solvent for solution for infusion

Product code: W64161001 Quantity: 1

Indicated for: pulmonary arterial hypertension

Route of administration: infusion

Substance: epoprostenol (antihypertensive)

ATC: B01AC09 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)

Epoprostenol is a medication used to treat severe pulmonary arterial hypertension, a condition that affects the blood vessels in the lungs and can lead to heart failure. This medicine works by dilating the blood vessels in the lungs, reducing pressure and improving the patient's exercise capacity. Epoprostenol is usually administered by continuous intravenous infusion under strict medical supervision.

Treatment with epoprostenol requires close monitoring, as the dose must be adjusted based on the patient's response and any side effects. It is important for patients to strictly follow the doctor's instructions and report any new or unusual symptoms.

Side effects may include headaches, facial flushing, nausea, diarrhea, or jaw pain. In rare cases, infections at the catheter site or severe drops in blood pressure may occur.

Epoprostenol is an essential treatment for patients with severe pulmonary arterial hypertension, but it requires continuous medical supervision to ensure the therapy's effectiveness and safety. Collaboration with the medical team is crucial for treatment success.

General data about EPOPROSTENOL 0.5mg

  • Substance: epoprostenol
  • Date of latest medicines list: 01-05-2019
  • Product code: W64161001
  • Concentration: 0.5mg
  • Pharmaceutical form: powder and solvent for solution for infusion
  • Quantity: 1
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: MERCURY PHARMACEUTICALS LTD - MAREA BRITANIE
  • Holder: PHARMNET PLUS S.R.L. - ROMANIA
  • Number: 351/2018/01
  • Shelf life: 3 years